|1.||Wounds and Injuries (Trauma)
|1.||Hofmeyr, G J: 12 articles (01/2006 - 01/2000)|
|2.||Hofmeyr, G Justus: 8 articles (01/2015 - 01/2012)|
|3.||Kok, Marjolein: 6 articles (05/2015 - 08/2008)|
|4.||Nassar, Natasha: 5 articles (01/2013 - 08/2003)|
|5.||Peat, Brian: 5 articles (01/2012 - 08/2003)|
|6.||Hannah, Mary E: 5 articles (04/2006 - 02/2002)|
|7.||Roberts, Christine L: 5 articles (03/2006 - 08/2003)|
|8.||Lau, T K: 4 articles (06/2015 - 03/2000)|
|9.||Vlemmix, Floortje: 4 articles (05/2015 - 03/2013)|
|10.||Hutton, Eileen K: 4 articles (01/2015 - 07/2003)|
|1.||Oxytocin (Pitocin)FDA LinkGeneric
03/01/1970 - "[The use of oxytocin in breech presentation]."
09/15/1965 - "OXYTOCIN IN BREECH PRESENTATION."
01/01/2005 - "Moxibustion may be beneficial in reducing the need for ECV, and decreasing the use of ocytocin, however there is a need for well-designed randomised controlled trials to evaluate moxibustion for breech presentation which report on clinically relevant outcomes as well as the safety of the intervention."
04/01/2002 - "On the other hand, Solihull showed more frequent oxytocin administration, fetal blood analysis, epidural anaesthesia, episiotomies, duration of labour > 13 hours, forceps, ventouse and emergency caesarean section deliveries from cephalic presentation, vaginal deliveries or emergency caesarean sections from breech presentation, resuscitation of the newborn using mask and/or drugs, maternal blood loss > 1 000 ml as well as abnormalities of placental separation. "
02/01/1982 - "4) Certain basic safety requirements such as available operating room facilities and adequate personnel for careful observation are mandatory, but other management policies that remain controversial include use of regional anesthesia, oxytocin administration, timing of hospital admission, artificial rupture of membranes, mode of delivery, proper method to evaluate the uterine scar, and delivery of fetuses in breech presentation and twins. "
|2.||Ritodrine (Yutopar)FDA Link
01/01/2005 - "To study the effect of ritodrine tocolysis on the success of external cephalic version (ECV) and to assess the role of ECV in breech presentation at our centre. "
11/19/1988 - "Reasons for exclusion were: refusal, antepartum haemorrhage, cardiac disease, breech presentation, multiple pregnancy, intrauterine death, and, after May 1986, ritodrine given two hours before delivery, anticoagulant treatment, and any condition needing a particular management of third stage. "
01/01/2005 - "External cephalic version significantly reduced the rate of cesarean section in breech presentation, and ritodrine tocolysis improved the success of ECV and should be offered to both nulliparous and parous women in the case of term breech presentation."
|3.||Bupivacaine (Bupivacaine Hydrochloride)FDA LinkGeneric
02/01/1975 - "These include the inadvisability of attempting to obtain a precise segmental block during the first stage of labour; the urgent need to avoid compression of the inferior vena cava by the uterus during labour and at the time of delivery; a preference for the routine use of bupivacaine in concentration of 0.375%, and for the plain solution irrespective of the concentration employed; and the advocacy of providing lumbar extradural analgesia in cases of breech presentation and multiple pregnancy. "
12/01/2007 - "Nulliparous women at term requesting external cephalic version for breech presentation were randomized to receive spinal analgesia (7.5 mg bupivacaine) or no analgesia before the external cephalic version. "
01/01/2002 - "Continuous epidural analgesia with bupivacaine 0.125% or bupivacaine 0.0625% plus sufentanil 0.25 microg.mL(-1): a study in singleton breech presentation."
10/01/2009 - "Parturients with singleton breech presentation (n=96) were randomized to receive CSE analgesia with bupivacaine 2.5mg and fentanyl 15 microg (CSE group) or intravenous fentanyl 50 microg (SYS group) before ECV attempt. "
|4.||Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
11/01/2010 - "To study the relationship between maternal thyrotrophin (TSH) and breech presentation at term. "
11/01/2010 - "High thyrotrophin levels at end term increase the risk of breech presentation."
01/01/1997 - "Cord blood thyrotrophin (TSH) levels of 134 patients with singleton pregnancies and breech presentation at delivery were compared with those of cephalic-presenting controls matched for mode of delivery, the presence of labour, parity, and the date of delivery. "
10/01/2001 - "To investigate the relationship between breech presentation, external cephalic version and levels of cord blood thyroid stimulating hormone. "
10/01/2001 - "In babies with a breech presentation born by elective caesarean section, previous attempts at external cephalic version had no effect on cord blood thyroid stimulating hormone levels. "
|5.||Terbutaline (Brethaire)FDA LinkGeneric
08/01/1995 - "The study spanned the period from 1985 to 1993, enrolling 113 subjects who presented to our OB/GYN Department with any type of breech presentation at 37 weeks' gestation or greater and met the following criteria: (1) absence of labour or ruptured membranes, (2) singleton pregnancy, (3) absence of medical or obstetrical complications and amniotic fluid index of greater than 8 cm. After a reassuring fetal assessment, IV terbutaline was given prior to an attempt at version. "
11/01/1997 - "Four of the 27 (15%) successful versions in the terbutaline group and three of the 14 (21%) successful versions in the placebo group spontaneously reverted to breech presentation. "
10/01/1986 - "Terbutaline (20 micrograms/min) was infused during 30 min in 17 women in whom a manual external manipulation of a breech presentation was going to be attempted. "
|6.||Dinoprostone (PGE2)FDA Link
04/01/1981 - "This study reports the influence of PGE2 gel on induction and labor in 13 primigravid patients with unfavorable cervixes and breech presentation. "
01/01/1998 - "Induction of labour with local application of PgE2 in breech presentation is still a much discussed problem. "
04/01/1981 - "Vaginal prostaglandin E2 gel and breech presentation."
01/01/1998 - "Our results show, despite is small case number, that with favourable pelvic scores and absence of cephalopelvic disproportion and fetal distress PgE2 induction can be done locally even for breech presentation."
01/01/1998 - "We aimed at studying the effect of local application of PgE2 (Prostin E2--3 mg) vaginal tablets for induction of labour in breech presentation. "
03/01/1993 - "It seems logical that use of intra-uterine pressure monitoring will provide additional safety in women with a scarred uterus, breech presentation, high parity, or apparent failure of response to induction or augmentation of labour with the usual dose rates of oxytocics, but this has not been established by appropriately sized clinical trials. "
04/01/1959 - "[Intravenous perfusion of oxytocics in breech presentation]."
|8.||Sufentanil (Sufenta)FDA LinkGeneric
|9.||Growth Hormone (Somatotropin)IBA
|10.||salicylhydroxamic acid (SHAM)IBA
03/01/2013 - "This was a multicentre randomised controlled trial in which 406 low-risk pregnant women with a fetus in ultrasound breech presentation, with a gestational age of 33-35 weeks, were assigned to (1) true moxibustion at point BL67 plus usual care; (2) moxibustion at SP1, a non-specific acupuncture point (sham moxibustion) plus usual care; or (3) usual care alone. "
|1.||Cesarean Section (Caesarean Section)
08/01/2011 - "Does caesarean section provide the best outcome for mother and baby in breech presentation? "
08/01/1998 - "The study was conducted because of the still considerable controversies about the variation in obstetric management in breech presentation, in combination with the still increasing caesarean section rate for this type of presentation, as well as doubt concerning the assumed improvement in neonatal and maternal morbidity and mortality obtained by increasing section rate in breeches. "
02/06/2010 - "For breech presentation, caesarean section, either antepartum (0.2, 0.1-0.3) or intrapartum (0.3, 0.2-0.4), was associated with improved perinatal outcomes, but also with increased risk of stay in neonatal ICU (2.0, 1.1-3.6; and 2.1, 1.2-3.7, respectively). "
06/15/1997 - "Based on their investigation the authors conclude, that in the group of fetuses whose estimated birthweight is predicted to be between 750 and 1250 grams by ultrasound examination, perinatal mortality and morbidity rates in breech presentation can be improved by performing caesarean section."
01/01/1991 - "ECV reduced the frequency of breech presentation during labour from 83% to 17% and that of caesarean section from 33% to 13%. "
04/01/2004 - "Acupuncture plus moxibustion is more effective than observation in revolving fetuses in breech presentation. "
01/01/2010 - "Relatively clear evidence emerged to suggest that moxibustion is effective for breech presentation. "
12/01/2012 - "Despite a lack of scientific evidence supporting the use of moxibustion to address breech presentation, pregnant women consider CAMs, in general, to be safe and effective. "
01/01/2001 - "Acupuncture stimulation, especially with moxibustion, is expected to serve as a safe and effective modality in the management of breech presentation in a clinical setting."
11/01/2009 - "To estimate the efficacy of moxibustion between 34 and 38 weeks of gestation to facilitate the cephalic version of fetuses in breech presentation and the acceptability of this method by women. "
|3.||Fetal Version (External Cephalic Version)
03/01/2014 - "external cephalic version (ECV) is a relatively simple and safe manoeuvre and a proven effective approach in the reduction of breech presentation at term. "
06/01/1999 - "The objectives of this trial were to assess if assuming the knee-chest position reduced the frequency of breech presentation at delivery, increased the success of the subsequent external cephalic version, or both, and to determine if this management plan reduced the need for cesarean delivery. "
05/01/2015 - "Neither a client nor a care-provider strategy improved the external cephalic version implementation rate for breech presentation, neither with regard to the number of version attempts offered nor the number of women accepting the procedure."
06/01/2015 - "Randomized trial of anaesthetic interventions in external cephalic version for breech presentation."
07/01/2008 - "A prospective observational study was performed including all patients undergoing a trial of external cephalic version for a breech presentation of at least 36 weeks of gestation between 1987 and 2001 in our center. "
01/01/2015 - "Randomised trials of ECV at or near term (with or without tocolysis) compared with no attempt at ECV in women with breech presentation. "
01/01/2012 - "Randomised trials of ECV at or near term (with or without tocolysis) compared with no attempt at ECV in women with breech presentation. "
03/01/2000 - "Phase 1 was to develop a scoring system from 53 versions with singleton pregnancy in breech presentation at term using a standard protocol with fetal monitoring, ultrasound assessment and tocolysis. "
02/01/1975 - "It appears that a cause of failur of the external version with tocolysis near term is the breech presentation with extended legs."
02/01/1975 - "The external version of breech presentation into vertex presentation with tocolysis near term is now the best method to avoid the disadvantages of a breech presentation for mother and child. "
|5.||Acupuncture Points (Acupuncture Point)
11/11/1998 - "The 130 subjects randomized to the intervention group received stimulation of acupoint BL 67 by moxa (Japanese term for Artemisia vulgaris) rolls for 7 days, with treatment for an additional 7 days if the fetus persisted in the breech presentation. "
01/01/2009 - "We included randomized controlled trials (RCTs) and controlled clinical trials (CCTs) on moxibustion, acupuncture or any other acupoint stimulating methods for breech presentation in pregnant women. "
01/01/2009 - "Moxibustion and other acupuncture point stimulation methods to treat breech presentation: a systematic review of clinical trials."
04/01/2008 - "A systematic review of studies assessing the effectiveness of acupuncture-type interventions (moxibustion, acupuncture, or electro-acupuncture) on acupuncture point BL 67 to correct breech presentation compared to expectant management, based on controlled trials. "
01/01/2007 - "The aim of the study was to evaluate cardiovascular effects and fetal behavior during moxibustion, acupuncture or acupuncture plus moxibustion applied on the BL.67 acupoint of women (beside the outer corner of the 5th toenail) in fetal breech presentation. "